To Develop and Manufacture an Inactivated SARS-CoV-2 Vaccine Using Blood Pathogen Reduction Technology

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: RAYMOND  GOODRICH
Organization: COLORADO STATE UNIVERSITY
Fiscal Year: 2024
Award: $850,444
Funding agency: National Institute of Allergy and Infectious Diseases

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases, including emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.

Terms: <2019-nCoV vaccine><Advanced Development><Animal Model><Animal Models and Related Studies><Blood><Blood Reticuloendothelial System><COVID-19 vaccine><Clinical><Communicable Diseases><Contracting Opportunities><Contracts><Disease Outbreaks><Emerging Communicable Diseases><Emerging Infectious Diseases><Formulation><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Outbreaks><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Safety><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Technology><Toxicology><Vaccines><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><determine efficacy><develop a vaccine><develop vaccines><development of a vaccine><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><evaluate efficacy><examine efficacy><immunogenicity><manufacture><model of animal><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><pathogen><response><stability testing><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine development><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>